• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

    3/30/23 8:00:00 AM ET
    $AXLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AXLA alert in real time by email
    • Long COVID Phase 2b/3 study may proceed under U.S. Investigational New Drug application
    • MHRA guidance aligns on key measurements for a Long COVID registration trial, including primary endpoint and trial design elements
    • Axcella presented at Long COVID forum co-sponsored by BIO and Solve M.E.
    • The Company repositioned its strategy to focus on Long COVID
    • Engaged an investment bank to act as a strategic advisor as we explore a range of strategic alternatives to maximize stakeholder value

    Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

    "The year 2022 was one of significant achievement for Axcella Therapeutics that was highlighted by the results from the Phase 2a of AXA1125 in patients with fatigue related to Long COVID and positive data from a preplanned interim analysis from the trial of AXA1125 in NASH," said Bill Hinshaw, President and Chief Executive Officer of Axcella. "In addition, the Company raised around $60 million, allowing completion of the Long COVID trial and positioning for regulatory interactions. The Company cleared a path forward for a registration study in Long COVID fatigue and focused the company and resources to support this opportunity."

    Recent Accomplishments and Developments

    • Statistically Significant and Meaningful Clinical Results in the Treatment of Long COVID Fatigue: Axcella's Phase 2a clinical trial results demonstrated the potential of AXA1125 to play an important role in treating patients suffering from Long COVID fatigue. Axcella's Phase 2a trial has been the only controlled trial to demonstrate statistically and clinically relevant improvement in fatigue in patients with Long COVID. This randomized, double-blind, placebo-controlled investigation evaluated the efficacy and safety of AXA1125 in patients with fatigue related to Long COVID. The study, which did not meet an experimental biomarker primary endpoint, found that subjects who received AXA1125 experienced clinically and statistically significant improvement in mental (p=0.0097) and physical (p=0.0097) fatigue scores compared to placebo subjects. Understanding of the relevant biological activity and safety were complemented by concurrent data generated in the NASH program.
    • FDA Clearance of IND for a Phase 2b/3 Trial: Axcella announced its Investigational New Drug (IND) application to initiate a Phase 2b/3 trial in the U.S. for AXA1125 in the treatment of Long COVID fatigue had been cleared by the U.S. Food and Drug Administration (FDA). The Company reported that it had received regulatory guidance from the FDA, supporting a trial that is designed to serve as the registration trial for patients with Long COVID fatigue. Fatigue is the most common symptom associated with Long COVID, impacting a majority of patients.
    • Regulatory Path to Registration of AXA1125 in Long COVID: The Company received regulatory guidance from The Medicines and Healthcare products Regulatory Agency (MHRA), the U.K.'s regulatory agency, supporting a single trial that could serve as the registration trial for patients with Long COVID fatigue, and aligning on key measurements, including primary endpoint and trial design.
    • Restructuring the Company to Advance AXA1125 in Long COVID Fatigue: Axcella discontinued its Phase 2b clinical trial of AXA1125 in NASH despite reporting positive data from a preplanned interim analysis in September. At 24 weeks, there were statistically significant and clinically relevant improvements in the liver stiffness measurement (LSM) compared to placebo in the high dose arm for all subjects and statistically significant improvements in other non-invasive tests of liver fat and stiffness. Axcella also realigned the organization to correspond to this shift in strategy and reprioritization of its programs.
    • Financial Performance: Axcella completed registered direct offerings in March 2022 and October 2022, yielding gross proceeds of approximately $59 million. Expenses for the three clinical trials and payments of about $27 million to extinguish the debt with SLR Investment Corp. led the Company to restructure in December and to explore a range of strategic alternatives to maximize stakeholder value. With respect to the Company's plans, no assurances can be made as to whether a strategic transaction will be recommended by the Board of Directors, and the Company does not intend to discuss developments with respect to the evaluation process unless a transaction is approved, or disclosure otherwise becomes appropriate.

    Financial Results

    Cash Position: As of December 31, 2022, cash and cash equivalents totaled $17.1 million, compared to cash, cash equivalents, and marketable securities of $55.0 million as of December 31, 2021. As mentioned above, subsequent to the close of 2021, the Company received approximately $59 million in gross proceeds from registered direct offerings of common stock. Based on the Company's current financial resources and forecasted operating plan, the Company believes that it will be able to operate into the second quarter of 2023.

    R&D Expenses: Research and development expenses for the quarter and year ended December 31, 2022 were $13.3 million and $57.0 million, respectively. Research and development expenses for the same periods ended December 31, 2021 were $12.5 million and $43.1 million, respectively. These increases are primarily the result of the costs to run multiple Phase 2 clinical trials.

    G&A Expenses: General and administrative expenses for the quarter and year ended December 31, 2022 were $3.5 million and $15.8 million, respectively. General and administrative expenses for the same periods ended December 31, 2021 were $4.7 million and $18.7 million, respectively. These decreases are primarily the result of lower non-cash stock-based compensation expenses from expense reversals on forfeited equity awards.

    Restructuring and impairment charges: Other operating expenses were $4.2 million for the quarter and year ended December 31, 2022 due to: (i) a $2.1 million impairment charge on its right-of-use operating lease asset, (ii) a $0.2 million impairment charge on its finance lease asset, and (iii) a $1.9 million charge for severance expenses, all related to the corporate restructuring.

    Other (expense) income: Other (expense) income, net for the quarter and year ended December 31, 2022 was $2.1 million and $4.2 million, respectively. Other (expense) income, net for the same periods ended December 31, 2021 was $0.7 million and $2.8 million, respectively. In December 2022, the Company repaid its debt with SLR Investment Corp. and recorded a $1.5 million loss on debt extinguishment. The remaining loss relates to legal fees related to the promissory note conversion in October 2022 in connection with the registered direct offering.

    Net Loss: Net loss for the quarter and year ended December 31, 2022 was $23.0 million, or $0.33 per basic and diluted share, and $81.2 million, or $1.49 per basic and diluted share, respectively. The net loss for the quarter and year ended December 31, 2021 was $17.9 million, or $0.46 per basic and diluted share, and $64.6 million, or $1.70 per basic and diluted share, respectively. These increases are primarily the result of higher expenses in 2022 for clinical trials, restructuring and impairment charges, and a debt extinguishment loss.

    Internet Posting of Information

    Axcella uses the "Investors and News" section of its website, www.axcellatx.com, as a means of disclosing material nonpublic information, to communicate with investors and the public, and for complying with its disclosure obligations under Regulation FD. Such disclosures include, but may not be limited to, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, and public conference calls and webcasts. The information that we post on our website could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

    About Axcella Therapeutics (NASDAQ:AXLA)

    Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). The Company's product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to reset multiple biological pathways, improve cellular energetics, and restore homeostasis. Axcella's pipeline includes lead therapeutic candidates for the treatment of Long COVID and non-alcoholic steatohepatitis (NASH). The Company's unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. For more information, please visit www.axcellatx.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the timing of the company's clinical trial data readouts, the outcome of strategic alternatives, restructuring the company to advance AXA1125 in Long COVID Fatigue and its financial condition and expected cash runway into the second quarter of 2023. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to the potential impact of COVID-19 on the company's ability to conduct and complete its ongoing or planned clinical studies and clinical trials in a timely manner or at all due to patient or principal investigator recruitment or availability challenges, clinical trial site shutdowns or other interruptions and potential limitations on the quality, completeness and interpretability of data the company is able to collect in its clinical trials of AXA1125, other potential impacts of COVID-19 on the company's business and financial results, including with respect to its ability to raise additional capital and operational disruptions or delays, changes in law, regulations, or interpretations and enforcement of regulatory guidance, whether data readouts support the company's clinical trial plans and timing, clinical trial design and target indications for AXA1125, the clinical development and safety profile of AXA1125 and its therapeutic potential, whether and when, if at all, the company's product candidates will receive approval from the FDA or other comparable regulatory authorities, potential competition from other biopharma companies in the company's target indications, and other risks identified in the company's SEC filings, including Axcella's Annual Report on Form 10-K, Quarterly Report on Form 10-Q and subsequent filings with the SEC. The company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Axcella disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. The company explicitly disclaims any obligation to update any forward-looking statements.

    Axcella Therapeutics

    Unaudited Condensed Consolidated Balance Sheets

    (in thousands)

     

     

     

     

     

     

     

    December 31,

     

    December 31,

     

     

    2022

     

    2021

    Assets:

     

     

     

     

    Cash and cash equivalents

     

    $

    17,147

     

    $

    23,574

    Marketable securities

     

     

    —

     

     

    31,474

    Other assets

     

     

    1,780

     

     

    2,679

    Total assets

     

    $

    18,927

     

    $

    57,727

    Liabilities and stockholders' equity:

     

     

     

     

    Accounts payable

     

    $

    4,707

     

    $

    4,301

    Accrued expenses and other current liabilities

     

     

    7,849

     

     

    5,849

    Current portion of operating lease liability

     

     

    1,592

     

     

    —

    Total current liabilities

     

     

    14,148

     

     

    10,150

    Long-term debt, net of discount

     

     

    —

     

     

    25,070

    Operating lease liability

     

     

    569

     

     

    —

    Other non-current liabilities

     

     

    46

     

     

    499

    Total liabilities

     

     

    14,763

     

     

    35,719

    Stockholders' equity

     

     

    4,164

     

     

    22,008

    Total liabilities and stockholders' equity

     

    $

    18,927

     

    $

    57,727

    Axcella Therapeutics

    Unaudited Condensed Consolidated Statements of Operations

    (in thousands, except share and per share data)

     

     

     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2022

     

     

     

    2021

     

     

     

    2022

     

     

     

    2021

     

    Operating expenses:

     

     

     

     

     

     

     

    Research and development

    $

    13,257

     

     

    $

    12,467

     

     

    $

    56,984

     

     

    $

    43,135

     

    General and administrative

     

    3,500

     

     

     

    4,736

     

     

     

    15,815

     

     

     

    18,711

     

    Restructuring and impairment charges

     

    4,189

     

     

     

    —

     

     

     

    4,189

     

     

     

    —

     

    Total operating expenses

     

    20,946

     

     

     

    17,203

     

     

     

    76,988

     

     

     

    61,846

     

    Loss from operations

     

    (20,946

    )

     

     

    (17,203

    )

     

     

    (76,988

    )

     

     

    (61,846

    )

    Other income (expense):

     

     

     

     

     

     

     

    Loss on extinguishment of debt

     

    (1,601

    )

     

     

    —

     

     

     

    (1,601

    )

     

     

    —

     

    Interest income (expense) and other income (expense), net

     

    (453

    )

     

     

    (688

    )

     

     

    (2,597

    )

     

     

    (2,782

    )

    Total other income (expense), net

     

    (2,054

    )

     

     

    (688

    )

     

     

    (4,198

    )

     

     

    (2,782

    )

    Net loss

    $

    (23,000

    )

     

    $

    (17,891

    )

     

    $

    (81,186

    )

     

    $

    (64,628

    )

    Net loss per share, basic and diluted

    $

    (0.33

    )

     

    $

    (0.46

    )

     

    $

    (1.49

    )

     

    $

    (1.70

    )

    Weighted average common shares outstanding, basic and diluted

     

    70,435,331

     

     

     

    38,847,669

     

     

     

    54,355,769

     

     

     

    38,110,420

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230330005233/en/

    Get the next $AXLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AXLA

    DatePrice TargetRatingAnalyst
    11/16/2021$10.00 → $12.00Buy
    Chardan Capital
    10/12/2021$6.00Outperform
    Noble Capital Markets
    9/22/2021$9.00 → $5.00Buy → Neutral
    Goldman Sachs
    7/30/2021Neutral → Underweight
    JP Morgan
    7/6/2021$14.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AXLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital reiterated coverage on Axcella Health with a new price target

      Chardan Capital reiterated coverage of Axcella Health with a rating of Buy and set a new price target of $12.00 from $10.00 previously

      11/16/21 9:26:58 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Noble Capital Markets initiated coverage on Axcella Health with a new price target

      Noble Capital Markets initiated coverage of Axcella Health with a rating of Outperform and set a new price target of $6.00

      10/12/21 8:46:44 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Health downgraded by Goldman Sachs with a new price target

      Goldman Sachs downgraded Axcella Health from Buy to Neutral and set a new price target of $5.00 from $9.00 previously

      9/22/21 6:18:00 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    Financials

    Live finance-specific insights

    See more
    • Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

      Phase 2b/3 study may proceed under U.S. Investigational New Drug application Study design now accepted by U.S. and U.K. regulatory authorities Axcella to present at Long COVID forum co-sponsored by BIO and Solve M.E. Axcella to host a conference call February 16 at 8:00 a.m. ET; To register, click here Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced its Investigational New Drug (IND) application to initiate a phase 2b/3 trial in the U.S. for AXA1125 in the treatment of Long COVID Fatigue has been cleared by the U.S. F

      2/15/23 4:10:00 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Therapeutics to Participate in the SVB Securities' 2023 Global Biopharma Conference

      Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that CEO Bill Hinshaw will present a company update at SVB Securities' 2023 Global Biopharma Conference, taking place virtually February 14-16, 2023. Details for Axcella's participation are as follows: Date:   Thursday, February 16, 2023 Time:   11:20 am Eastern Time Webcast:   https://wsw.com/webcast/svb8/axla/1608786 The conference call webcast will be accessible in the Investors & News section on the company's website at www.axcellatx.com. An archive

      2/9/23 4:45:00 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue

      MHRA guidance aligns on key measurements for a registration trial, including primary endpoint and trial design elements IND for phase 2b/3 trial submitted to the FDA Axcella to host a conference call Tuesday, January 24 at 8:00 a.m. ET; To register, click here Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company pioneering novel approaches to treating complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, announced a regulatory path to registration of AXA1125 in the treatment of Long COVID Fatigue. The company reported that it had received regulatory guidance from The Medicines and Healthcare products Regulatory Agency (MHRA), the U

      1/23/23 4:15:00 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Axcella Health Inc.

      25-NSE - Axcella Health Inc. (0001633070) (Subject)

      2/15/24 8:54:23 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Health Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Axcella Health Inc. (0001633070) (Filer)

      12/22/23 4:30:17 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Health Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets

      8-K - Axcella Health Inc. (0001633070) (Filer)

      12/19/23 4:45:12 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Koziel Margaret

      4 - Axcella Health Inc. (0001633070) (Issuer)

      2/24/23 4:18:54 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Fehlner Paul

      4 - Axcella Health Inc. (0001633070) (Issuer)

      2/24/23 4:17:30 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Hinshaw William

      4 - Axcella Health Inc. (0001633070) (Issuer)

      2/24/23 4:18:21 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Axcella Announces Reverse Stock Split Effective September 19, 2023

      – AXLA common stock expected to begin trading on a split-adjusted basis on September 19, 2023 – Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that its Board of Directors has approved a 1-for-25 reverse stock split of the Company's common stock. The reverse stock split will become effective at 5:00 p.m. Eastern Time on September 18, 2023, after close of trading on The Nasdaq Global Market. The Company's common stock is expected to commence trading on a split-adjusted basis when the markets open on Septembe

      9/14/23 4:30:00 PM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Granted Patent for Long COVID Fatigue Treatment

      Claims cover methods of treating a subject presenting with fatigue from post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, with Candidate AXA1125 Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,737,999 with claims covering methods of use of Candidate AXA1125, for treating a subject having post-acute sequelae of COVID-19 (PASC), a/k/a Long COVID, particularly fatigue. The patent was issued on August 29, 2023, with anticip

      8/29/23 8:00:00 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Axcella Reports Second Quarter Financial Results and Provides Business Update

      AXA1125 remains the most advanced product to help patients experiencing fatigue post acute COVID-19 The Company continues to pursue a strategic alternative for stakeholders Axcella Therapeutics (NASDAQ:AXLA), a clinical-stage biotechnology company focused on pioneering a new approach to address the biology of complex diseases using compositions of endogenous metabolic modulators (EMMs), today announced financial results for the second quarter ended June 30, 2023 and provided a business update. "Patients are seeking relief from Long COVID fatigue. Axcella's proprietary composition of amino acids in AXA1125 in Long COVID fatigue is potentially an important step to help people mainta

      8/3/23 7:30:00 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Axcella Health Inc. (Amendment)

      SC 13G/A - Axcella Health Inc. (0001633070) (Subject)

      9/11/23 8:23:54 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Axcella Health Inc. (Amendment)

      SC 13G/A - Axcella Health Inc. (0001633070) (Subject)

      2/14/23 6:06:00 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Axcella Health Inc. (Amendment)

      SC 13G/A - Axcella Health Inc. (0001633070) (Subject)

      2/9/23 8:23:46 AM ET
      $AXLA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AXLA
    Leadership Updates

    Live Leadership Updates

    See more
    • Flagship Pioneering Bolsters Executive Team with Appointment of Michelle C. Werner as CEO-Partner and CEO of Alltrna

      Werner Brings More Than Two Decades of Pharmaceutical Leadership to the Role CAMBRIDGE, Mass., April 11, 2022 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced it has strengthened its executive leadership team with the appointment of Michelle C. Werner to the dual role of CEO-Partner of Flagship Pioneering and Chief Executive Officer of Alltrna. Werner brings to Flagship significant experience as a global pharmaceutical leader spanning both Commercial and Research and Development (R&D) responsibilities.  Werner most recently served as Wo

      4/11/22 6:00:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations
    • Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs

      CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Anne Pariser, M.D., as Vice President, Medical and Regulatory Affairs. Prior to joining Alltrna, Dr. Pariser was the Director of the Office of Rare Diseases Research (ORDR) at the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), whose mission is to advance rare diseases research through a variety of research programs. Prior to ORDR, she worked at the U.S. Food and Drug Administration (FDA) Center for

      2/28/22 9:00:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations
    • INVAIO SCIENCES STRENGTHENS ITS BOARD OF DIRECTORS WITH THE APPOINTMENT OF HUGH GRANT

      CAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agricultural, sustainability, and environmental challenges, today announced the appointment of Hugh Grant to its Board of Directors. Grant brings nearly 40 years of agricultural and corporate leadership, including as Chairman, President, and Chief Executive Officer of the former Monsanto Company, a global provider of technology-based solutions and agricultural products. During h

      2/15/22 10:05:00 AM ET
      $AXLA
      $CDAK
      $DNLI
      $EVLO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medicinal Chemicals and Botanical Products
      Biotechnology: Pharmaceutical Preparations